Safinamide – A Unique Treatment Targeting Both Dopaminergic and Non-Dopaminergic Systems

European Neurological Review, 2016;11(2):101–5 DOI: https://doi.org/10.17925/ENR.2016.11.02.101

Abstract:

Dopaminergic replacement therapies are prescribed widely to improve motor problems in Parkinson’s disease (PD). However, as the disease progresses, the response to levodopa (l-dopa) doses becomes shorter and patients experience symptom recurrence at the end of the dose effect. These so-called OFF periods may become refractory to treatment, and may become associated with disabling motor fluctuations or dyskinesias. In addition to dopamine, glutamate excitotoxicity, resulting from disturbance of the homeostatic balance of neurotransmitters and elevated extracellular levels of glutamate, is potentially an important therapeutic target. Safinamide has been investigated in phase III clinical trials as adjunct therapy to l-dopa in mid- to late-stage fluctuating PD. Adding safinamide to l-dopa increases the time patients’ symptoms are controlled – so-called ON time, without increasing troublesome dyskinesia. Although safinamide has dopaminergic actions, recent data have suggested that the long-term effects of safinamide on dyskinesia are related to safinamide state- and use-dependent inhibition of sodium channels and stimulated glutamate release, rather than reduced dopaminergic stimulation. Safinamide’s unique dual mechanism of action makes it a valuable treatment option for fluctuating PD patients.
Keywords: Dopamine, glutamate, Parkinson’s disease, safinamide
Disclosure: Jaime Kulisevsky has received honoraria for lecturing or advisory boards from UCB, Zambon, Lundbeck and Abbvie, and research support from Instituto de Salud Carlos III, Spain. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.
Received: August 15, 2016 Accepted October 04, 2016
Correspondence: Jaime Kulisevsky, Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Universitat Autónoma de Barcelona, Mas Casanovas 90 08041 Barcelona, Spain. E: jkulisevsky@santpau.cat
Support: The publication of this interview was funded by Zambon SpA. The views and opinions expressed are those of the author and do not necessarily reflect those of Zambon SpA.
Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, with a prevalence that increases with age: 41 in 100,000 in the age group 40–49, rising to 1,903 in 100,000 in those aged over 80 years.1 PD is characterised by striatal dopamine deficiency resulting from progressive degeneration of dopaminergic cells in the pars compacta of the substantia nigra, the brain region responsible for motor control.2 Symptoms of PD include bradykinesia, rigidity, tremor, gait and postural abnormalities, and speech difficulty,3 as well as non-motor symptoms including cognitive dysfunction, mood disorders, sleep disturbance and pain.4

Although PD is incurable, symptoms can be alleviated using dopaminergic therapies including the dopamine precursor levodopa (l-dopa), dopamine agonists and monoamine oxidase (MAO)-B inhibitors that block dopamine degradation, thereby helping restore dopamine levels in the brain.5,6 L-dopa is currently the standard treatment for motor symptoms in PD, but its long-term use has important limitations.5 As the disease progresses, the response to l-dopa doses becomes shorter and patients motor fluctuations, which involve periods of being ON, during which the patient experiences a positive response to medication, and being OFF, during which the patient experiences a re-emergence of the symptoms suppressed during the ON state.7,8 Furthermore, symptoms of PD, including gait and tremor, gradually become resistant to l-dopa.8 Other limitations of the use of l-dopa include the fact that it does not prevent PD progression,9 and many non-motor symptoms do not respond well to l-dopa.9

As well as motor fluctuations, abnormal involuntary movements, known as l-dopa-induced dyskinesia (LID), develop with prolonged use of l-dopa; these may occur at peak effect of l-dopa, at the beginning and end of dose, or between doses (see Figure 1).8,10–12 These movements usually involve the face and the side of the body that is initially affected by the disease, but they commonly progress and affect the neck, upper and lower limbs, and body axis. Chorea and dystonia are the most frequent forms of LIDs, but ballismus and myoclonus can also appear.13,14 Around 40% of patients experience motor fluctuations and LID after 4-6 years of treatment with l-dopa,14 and 60% to 100% may experience LID after 10 years.15,16

Motor fluctuations are the result of alterations of the functional organisation of the basal ganglia circuitry following long-term exposure to l-dopa. Progressive degeneration of the nigro-striatal dopaminergic pathway reduces the ability of nerve terminals to store and release dopamine.17 As a result of this loss of storage capacity, l-dopa induces a more pulsatile stimulation of postsynaptic dopamine receptors, consistent with l-dopa’s short (90-minute) half-life and its rapid cycling pharmacokinetics. This pulsatile stimulation causes functional changes within the basal ganglia, leading to involuntary movements and altered neural activity in the basal ganglia, thalamus cerebral cortex.17

References:
1. 1. Pringsheim T, Jette N, Frolkis A, et al., The prevalence of Parkinson’s disease: a systematic review and meta-analysis, Mov Disord, 2014;29:1583–90.
2. EMC, Amantadine hydrochloride: SPC. Available at: www. medicines.org.uk/emc/medicine/32086 (accessed 19 July 2016).
3. Lang AE, Lozano AM, Parkinson’s disease. First of two parts, N Engl J Med, 1998;339:1044-53.
4. Chaudhuri KR, Schapira AH, Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment, Lancet Neurol, 2009;8:464–74.
5. Grosset DG, Macphee GJ, Nairn M, et al., Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines, BMJ, 2010;340:b5614.
6. Birkmayer W, Hornykiewicz O, The effect of l-3,4- dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism, Parkinsonism Relat Disord, 1998;4:59–60.
7. Jenner P, Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson’s disease, Neurol Clin, 2013;31:S17–35.
8. Aquino CC, Fox SH, Clinical spectrum of levodopa-induced complications, Mov Disord, 2015;30:80–9.
9. Olanow CW, Agid Y, Mizuno Y, et al., Levodopa in the treatment of Parkinson’s disease: current controversies, Mov Disord, 2004;19:997–1005.
10. Chase TN, Holden EM, Brody JA, Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis, Arch Neurol, 1973;29:328–33.
11. Huot P, Johnston TH, Koprich JB, et al., The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease, Pharmacol Rev, 2013;65:171–222.
12. Thanvi B, Lo N, Robinson T, Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment, Postgrad Med J, 2007;83:384–8.
13. Bargiotas P, Konitsiotis S, Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments, Neuropsychiatr Dis Treat, 2013;9:1605–17.
14. Ahlskog JE, Muenter MD, Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord, 2001;16:448–58.
15. Rascol O, Brooks DJ, Korczyn AD, et al., A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa, N Engl J Med, 2000;342:1484–91.
16. Van Gerpen JA, Kumar N, Bower JH, et al., Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990, Arch Neurol, 2006;63:205–9.
17. de la Fuente-Fernandez R, Sossi V, Huang Z, et al., Levodopainduced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias, Brain, 2004;127:2747–54.
18. Sharma JC, Macnamara L, Hasoon M, et al., Cascade of levodopa dose and weight-related dyskinesia in Parkinson’s disease (LD-WD-PD cascade), Parkinsonism Relat Disord, 2006;12:499–505.
19. Schrag A, Quinn N, Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study, Brain, 2000;123 ( Pt 11):2297–305.
20. Chapuis S, Ouchchane L, Metz O, et al., Impact of the motor complications of Parkinson’s disease on the quality of life, Mov Disord, 2005;20:224–30.
21. Horstink M, Tolosa E, Bonuccelli U, et al., Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease, Eur J Neurol, 2006;13:1186–202.
22. Fox SH, Katzenschlager, R., Lim, S.Y., et al.,, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease, Mov Disord, 2011;26:Suppl 3:S2–4.
23. Antonini A, Tolosa E, Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management, Expert Rev Neurother, 2009;9:859–67.
24. Durif F, Debilly B, Galitzky M, et al., Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebocontrolled study, Neurology, 2004;62:381–8.
25. Haas SJ, Hill R, Krum H, et al., Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003, Drug Saf, 2007;30:47–57.
26. Alvir JM, Lieberman JA, Safferman AZ, et al., Clozapine-induced agranulocytosis. Incidence and risk factors in the United States, N Engl J Med, 1993;329:162–7.
27. Katzenschlager R, Hughes A, Evans A, et al., Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges, Mov Disord, 2005;20:151–7.
28. Olanow CW, Kieburtz K, Odin P, et al., Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study, Lancet Neurol, 2014;13:141–9.
29. LeWitt PA, Lyons KE, Pahwa R, et al., Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study, Neurology, 2007;68:1262–7.
30. Benabid AL, Deep brain stimulation for Parkinson’s disease, Curr Opin Neurobiol, 2003;13:696–706.
31. Hatano T, Kubo SI, Shimo Y, et al., Unmet needs of patients with Parkinson’s disease: interview survey of patients and caregivers, J Int Med Res, 2009;37:717–26.
32. Politis M, Wu K, Molloy S, et al., Parkinson’s disease symptoms: the patient’s perspective, Mov Disord, 2010;25:1646–51.
33. Blandini F, Porter RH, Greenamyre JT, Glutamate and Parkinson’s disease, Mol Neurobiol, 1996;12:73–94.
34. Lange KW, Kornhuber J, Riederer P, Dopamine/glutamate interactions in Parkinson’s disease, Neurosci Biobehav Rev, 1997;21:393–400.
35. Barone P, Neurotransmission in Parkinson’s disease: beyond dopamine, Eur J Neurol, 2010;17:364–76.
36. Brotchie JM, Nondopaminergic mechanisms in levodopainduced dyskinesia, Mov Disord, 2005;20:919–31.
37. Jia M, Njapo SA, Rastogi V, et al., Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection, CNS Drugs, 2015;29:153–62.
38. Fox SH, Non-dopaminergic treatments for motor control in Parkinson’s disease, Drugs, 2013;73:1405–15.
39. Onofrj M, Bonanni L, Thomas A, An expert opinion on safinamide in Parkinson’s disease, Expert Opin Investig Drugs, 2008;17:1115–25.
40. Marzo A, Dal Bo L, Monti NC, et al., Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity, Pharmacol Res, 2004;50:77–85.
41. Dezsi L, Vecsei L, Safinamide for the treatment of Parkinson’s disease, Expert Opin Investig Drugs, 2014;23:729–42.
42. Pevarello P, Traquandi G, Bonsignori A, et al., Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety, Bioorg Med Chem Lett, 1999;9:1783–8.
43. Stoof JC, Booij J, Drukarch B, et al., The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a noncompetitive way, Eur J Pharmacol, 1992;213:439–43.
44. Johnson JW, Kotermanski SE, Mechanism of action of memantine, Curr Opin Pharmacol, 2006;6:61–7.
45. Caccia C, Maj R, Calabresi M, et al., Safinamide: from molecular targets to a new anti-Parkinson drug, Neurology, 2006;67:S18–23.
46. Salvati P, Maj R, Caccia C, et al., Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound, J Pharmacol Exp Ther, 1999;288:1151–9.
47. Melloni E, Brugnoli, E., Caccia, C. et al Safinamide and glutamate release: new insights, Parkinsonism Relat Disord, 2016;22:e177.
48. Gregoire L, Jourdain VA, Townsend M, et al., Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys, Parkinsonism Relat Disord, 2013;19:508–14.
49. Borgohain R, Szasz J, Stanzione P, et al., Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations, Mov Disord, 2014;29:229–37.
50. Borgohain R, Szasz J, Stanzione P, et al., Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease, Mov Disord, 2014;29:1273–80.
51. Anand R, Lucini V, Forrest E, et al.,, Early onset of efficacy of safinamide on motor fluctuations in PD patients on L-dopa and other PD medications (SETTLE study), Mov Disord, 2014;29:1273–80.
52. Schapira A, Fox S, Hauser RA, et al., Safinamide add on to L-dopa: a randomized, placebo-controlled, 24-week global trial in patients with Parkinson’s Disease (PD) and motor fluctuations (SETTLE), Presented at the 65th American Academy of Neurology Annual Meeting, San Diego, CA, USA, 16–23 March 2013.
53. EMA, Safinamide: Summary of Product Characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002396/ WC500184965.pdf (accessed 1 July 2016).
54. Cattaneo C, Ferla RL, Bonizzoni E, et al., Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis, J Parkinsons Dis, 2015;5:475–81.
55. Cattaneo C, Sardina M, Bonizzoni E, Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE, J Parkinsons Dis, 2016;6:165–73.
56. Parkinson Study Group, A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study, Arch Neurol, 2005;62:241–8.
Keywords: Dopamine, glutamate, Parkinson’s disease, safinamide